GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

Sept 15 (Reuters) - GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based ...

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate (ADC). The small cell lung cancer (SCLC) trial hit its primary endpoint, although the B7-H3-dire ...

H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN ...

Aug 24 (Reuters) - GSK (GSK.L), opens new tab said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S.

Bernstein's 23rd Annual Pan-European Strategic Decisions Conference September 9, 2026 4:00 AM EDTCompany ParticipantsJulie Brown - CFO ...

For Texas A&M fans, a new football season means new episodes of 12th Man Productions' "The Pulse," which originally aired once a week and provides in-depth coverage of every game, including interviews ...

Through just two games, both blowout victories, David Pollack doesn't believe Texas A&M will make it back to the College Football Playoff. According to The Athletic's recent article, Texas A&M and ...